



Stephen Thompson

Brandon Capital Partners

Managing Director

Stephen is a founding partner of Brandon Capital Partners.

Before moving to Australia, Stephen was a Director of Apax Partners based in London. Previously, he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California.

Stephen is a former director of Elastagen, (acquired by Allergan in 2018), and his current directorships include;, MecRx Pty Ltd, OncoRes Medical P/L, Respirion Pharmaceuticals P/L and Vaxxas P/L. He is also a Director of the Australian Investment Council (formerly AVCAL). Stephen has an Honours degree in Immunology and Biochemistry, a PhD in Immunology from Kings College London and an MBA, specialising in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors.

